Solriamfetol

(Sunosi)

Solriamfetol

Drug updated on 11/14/2023

Dosage FormTablet (oral: 75 mg, 150 mg)
Drug ClassMultiple
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • Indicated to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA).

Product Monograph / Prescribing Information

Document TitleYearSource
Sunosi (solriamfetol) Prescribing Information. 2022Axsome Therapeutics, Inc., New York, NY

Systematic Reviews / Meta-Analyses

Clinical Practice Guidelines